


U.S.S.N. 09/625,963

Filed: July 26, 2000

CLEAN VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121



RECEIVED  
NOV 19 2002  
TECH CENTER 1600/2000

**Clean Version of Amended Claims**  
**Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)**

1. (Four times amended) A peptide having at least 9 but fewer than 100 amino acids, which peptide comprises the amino acid sequence RMFPNAPYL (SEQ ID NO:1), and wherein the peptide is capable of:

- D1
- (a) binding to HLA-A0201; or
  - (b) being processed by an antigen presenting cell so that a fragment is produced which is able to bind to HLA-A0201.

D2

5. (Amended) A peptide according to claim 1 wherein the peptide is capable of binding to HLA-A0201 and, when bound to HLA-A0201, the peptide-bound HLA-A0201 is capable of eliciting the production of a cytotoxic T lymphocyte (CTL) which recognises a cell which aberrantly expresses a polypeptide comprising the given amino acid sequence.

D3

7. (Three times Amended) A peptide according to claim 1 consisting of the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

D4

15. (Twice Amended) A pharmaceutical composition comprising the peptide of Claim 1 and a pharmaceutically acceptable carrier.

D5

19. (Three times Amended) A vaccine for a tumor cell in which HLA-A0201 is expressed and WT-1 is over expressed, the vaccine comprising a peptide according to claim 1.

D6

44. (Amended) The peptide of claim 1 consisting of from 9 to 12 amino acids.